Analyst Ratings For Arena Pharmaceuticals (NASDAQ:ARNA)
Today, Citigroup reiterated its Positive rating on Arena Pharmaceuticals (NASDAQ:ARNA) with a price target of $62.00.
Some recent analyst ratings include
- 3/21/2018-Citigroup Reiterated Rating of Positive .
- 3/20/2018-Wells Fargo Reiterated Rating of Positive .
- 3/20/2018-Needham & Company LLC Upgrade from a “Hold ” rating to a ” Buy” rating.
- 1/17/2018-Credit Suisse Group initiated coverage with a Outperform rating.
- 1/17/2018-Leerink Swann Reiterated Rating of Outperform .
- 1/17/2018-Cantor Fitzgerald Reiterated Rating of Buy.
Recent Insider Trading Activity For Arena Pharmaceuticals (NASDAQ:ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) has insider ownership of 1.88% and institutional ownership of 73.31%.
- On 5/12/2017 Amit Munshi, Insider, bought 25,000 with an average share price of $1.19 per share and the total transaction amounting to $29,750.00.
- On 4/26/2017 Amit Munshi, Insider, bought 50,000 with an average share price of $1.41 per share and the total transaction amounting to $70,500.00.
- On 6/13/2016 Christine Anna White, Director, sold 18,728 with an average share price of $1.99 per share and the total transaction amounting to $37,268.72.
- On 3/30/2015 Randall E Woods, Director, sold 76,268 with an average share price of $4.49 per share and the total transaction amounting to $342,443.32.
- On 3/17/2015 Steven W Spector, EVP, sold 70,000 with an average share price of $5.00 per share and the total transaction amounting to $350,000.00.
- On 1/8/2015 Steven W Spector, EVP, sold 45,000 with an average share price of $6.26 per share and the total transaction amounting to $281,700.00.
- On 1/7/2015 William R Shanahan Jr, SVP, sold 50,000 with an average share price of $5.49 per share and the total transaction amounting to $274,500.00.
Recent Trading Activity for Arena Pharmaceuticals (NASDAQ:ARNA)
Shares of Arena Pharmaceuticals closed the previous trading session at with 660760 shares trading hands.
